Feb 16, 2023 / 04:20PM GMT
Joseph Patrick Schwartz - SVB Securities LLC, Research Division - Senior MD of Rare Diseases & Senior Research Analyst
Hello. Welcome to this fireside chat with BioMarin Pharmaceuticals. I'm Joe Schwartz, Senior Equity Research Analyst at SVB Securities. It's my pleasure to be joined by management, including JJ Bienaime, Jeff Ajer and Brian Mueller. Thank you so much for joining us.
Maybe will start by having you, JJ, give us a quick rundown of the company's key initiatives and catalysts that we should look forward to over the balance of this year, and then we'll go to Q&A.
Jean-Jacques Bienaime - BioMarin Pharmaceutical Inc. - Chairman & CEO
Sounds good. Thank you, Joe, and good morning, everyone. Thank you for joining us today. As you know, we are less than 2 weeks away from our Q4 full year financial results call. So we would like to avoid specifics of the fourth quarter.
In January, we provided a high-level strategy and framework for growth of the company in the near term and by mid-decade and throughout the
Biomarin Pharmaceutical Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers